Morning Market Gainers

shares jumped 174.81 percent to $3.60 after the company agreed to be acquired by

for $912 million.

shares surged 57.67 percent to $62.83 after the company agreed to be acquired at $4 billion, or $63.25 per share in an all-cash transaction valued.

gained 32.20 percent to $21.76 after the company reported that its RHB-105 Phase 3 study met its primary endpoint.

jumped 23.93 percent to $5.04. Ruthigen and Pulmatrix stockholders approved the merger between Ruthigen and Pulmatrix.

shares rose 10.27 percent to $7.62 after the company reported the FDA approval of Ovation iX(TM) Iliac Stent Graft.

shares climbed 9.57 percent to $1.03 as the company launched wearable pain relief technology.

shares jumped 6.24 percent to $8.87. Standard Pacific and

agreed to merge in an all-stock transaction.

shares surged 4.20 percent to $3.72. JP Morgan initiated coverage on Idera Pharmaceuticals with a Overweight rating.

shares surged 1.42 percent to $183.38 after the company reported new data from HGB-205 study. Philip Gregory, D. Phil., joined bluebird bio as Chief Scientific Officer. JP Morgan maintained bluebird bio with a Overweight and raised the price target from $200.00 to $244.00.